Background Acyl-CoA binding domain containing protein 5 (ACBD5) is a peroxisomal membrane protein with a cytosolic acyl-CoA binding domain. Because of its acyl-CoA binding domain, ACBD5 has been assumed to function as an intracellular carrier of acyl-CoA esters. In addition, a role for ACBD5 in pexophagy has been suggested. However, the precise role of ACBD5 in peroxisomal metabolism and/or functioning has not yet been established. Previously, a genetic ACBD5 deficiency was identified in three siblings with retinal dystrophy and white matter disease. We identified a pathogenic mutation in ACBD5 in another patient and studied the consequences of the ACBD5 defect in patient material and in ACBD5-deficient HeLa cells to uncover this role. Methods We studied a girl who presented with progressive leukodystrophy, syndromic cleft palate, ataxia and retinal dystrophy. We performed biochemical, cell biological and molecular studies in patient material and in ACBD5-deficient HeLa cells generated by CRISPR-Cas9 genome editing. Results We identified a homozygous deleterious indel mutation in ACBD5, leading to complete loss of ACBD5 protein in the patient. Our studies showed that ACBD5 deficiency leads to accumulation of very long-chain fatty acids (VLCFAs) due to impaired peroxisomal β-oxidation. No effect on pexophagy was found. Conclusions Our investigations strongly suggest that ACBD5 plays an important role in sequestering C26-CoA in the cytosol and thereby facilitates transport into the peroxisome and subsequent β-oxidation. Accordingly, ACBD5 deficiency is a novel single peroxisomal enzyme deficiency caused by impaired VLCFA metabolism, leading to retinal dystrophy and white matter disease.
INTRODUCTION
Peroxisomes play an important role in a number of essential metabolic pathways, including the biosynthesis of ether phospholipids and bile acids, the α-oxidation and β-oxidation of fatty acids and the detoxification of glyoxylate and of reactive oxygen species generated in peroxisomes, that is, hydrogen peroxide and superoxide. 1 Defects in human genes encoding peroxisomal proteins can result in different peroxisomal disorders with variable severity ranging from early lethality to subtle neurosensory abnormalities. 2 3 The peroxisomal disorders are subdivided in two main classes: (1) the peroxisome biogenesis disorders, which include the Zellweger spectrum disorders and Rhizomelic chondrodysplasia punctata (RCDP) type 1 and 5 and (2) the single peroxisomal enzyme deficiencies. 3 In the first class, multiple peroxisomal metabolic pathways are impaired, resulting in multiple metabolic abnormalities, whereas in the second class, only the metabolic pathways, in which the defective enzyme participates, are impaired. 1 The clinical, biochemical and genetic spectrum of peroxisomal disorders is broad and still expanding. For example, recently, Heimler syndrome was recognised as a mild presentation of the Zellweger spectrum, 4 and two novel types of RCDP (4 and 5) 5 6 were identified. In this paper, we report a novel peroxisomal single enzyme deficiency affecting the peroxisomal β-oxidation of very long-chain fatty acids (VLCFAs), due to a deficiency of acyl-CoA binding domain containing protein 5 (ACBD5).
ACBD5 is a peroxisomal membrane protein of 54.7 kDa with a C-terminal membrane-spanning region and an N-terminal cytosolic acyl-CoA binding domain. The peroxisomal localisation of ACBD5 was established by proteomic analysis of purified peroxisomes from mouse kidney, 7 rat liver 8 9 and human liver, 10 and confirmed by colocalisation studies in cultured cells. 7 8 11 Because of its acyl-CoA binding domain, ACBD5 has been assumed to function as an intracellular carrier of acyl-CoA esters. 12 More recently, a role for ACBD5 in the degradation of peroxisomes, that is, pexophagy, has been suggested mainly based on sequence similarity with the ATG37 protein of the yeast Pichia pastoris, which was implicated in this process. 11 However, the precise role of ACBD5 in peroxisomal metabolism and functioning had not been established.
Previously, a heterozygous missense variant in ACBD5 was reported to cosegregate with autosomal dominant thrombocytopenia by Punzo et al, 13 but a year later, Pippucci et al 14 reported that the actual pathogenic mutations in this family and seven additional families causing autosomal dominant thrombocytopenia are in the ANKRD26 and not the ACBD5 gene. In 2013, exome sequencing of a large cohort of patients with retinal dystrophy identified three siblings with a genetic ACBD5 deficiency caused by a homozygous splice site mutation, but the pathogenic, physiological and functional consequences of the defect were not studied. 15 The retinal dystrophy was described as syndromic in the three siblings because of the combination with severe white matter disease and spastic paraparesis.
Here, we report in detail the clinical presentation of an ACBD5-deficient patient, who presented with progressive leukodystrophy associated with syndromic cleft palate, ataxia and retinal dystrophy. We furthermore show that the ACBD5 defect leads to accumulation of VLCFAs as a result of an impaired peroxisomal β-oxidation of these fatty acids. Based on our findings, we postulate that ACBD5 functions as a peroxisomal membranebound receptor for VLCFA-CoAs.
MATERIALS AND METHODS Patient
The parents of the patient signed an informed consent approving the research.
Metabolic, biochemical and microscopical analyses
Concentrations of VLCFAs, phytanic acid and pristanic acid were determined in plasma as described in ref. 16 and VLCFAs and C26:0 lysophosphatidylcholine (C26:0 lysoPC) were measured in cultured cells as described previously. 17 18 Peroxisomal β-oxidation of the VLCFA hexacosanoic acid (C26:0) and pristanic acid were measured as described. 19 A D3-C22:0 loading test was performed by loading cells for 3 days with deuterated (D3) C22:0 followed by fatty acid analysis with tandem mass spectrometry, essentially as previously described, 20 but with D3-C22:0 instead of D3-C24:0.
Immunoblot analysis was performed with cell homogenates, which were separated by SDS-polyacrylamide gel electrophoresis, and subsequently transferred onto a nitrocellulose membrane using semidry blotting. We used rabbit polyclonal antibodies against ACBD5 (HPA012145, Sigma, directed against aa161-301, and AP9143a, Abgent, directed against aa69-98) at a 1:1000 dilution and mouse monoclonal antibodies against α-tubulin (T6199, Sigma) at a 1:2000 dilution or against β-actin (A5441, Sigma Alderich) at a 1:10.000 dilution. For visualisation, we used the secondary antibodies IRDye 800 CW goat anti-rabbit and/or IRDye 680 CW donkey anti-mouse with the Odyssey Infrared Imaging System (LI-COR Biosciences, Nebraska, USA).
For immunofluorescence microscopy, skin fibroblasts were cultured on cover slips to a confluency of approximately 60%-70%. Cells were fixed and permeabilised with phosphatebuffered saline (PBS, Fresenius Kabi GmbH, Austria) solution containing 2% paraformaldehyde (Merck 8.18715.0100) and 0.1% Triton X-100 (BIO RAD 161-0407; 20 0 ). After inactivating Triton X-100 with 100 mM ammonium chloride (Merck 1.01145.1000; 10 0 ), the cells were consecutively incubated with first and secondary antibodies and streptavidin-fluorescein isothiocyanate (FITC) complex (DAKO F 422) diluted in 1% bovine serum albumin (BSA) in PBS solutions for 45 min. The glass slides were fixed on objective slides with the mounting medium Vectashield H1000 (Brunswick) and imaged using the fluorescence microscope Zeiss Axio Observer A1. We used primary antibodies against catalase (mouse monoclonal, Mab 17E10, own generation), ACBD5 (rabbit polyclonal, Sigma, HPA012145, diluted 1:500) and PMP70 (rabbit polyclonal, Zymogen, 718300, diluted 1:500), and as secondary antibodies Alexa Fluor 555 Rabbit IgG (Z25305, ThermoFisher, diluted 1:500) or goat anti-mouse IgG antibody (DAKO, E433, diluted 1:200) or streptavidin-FITC complex (Bender Medsystems, diluted 1:200).
Cell culturing, transfections and functional complementation
Primary skin fibroblasts and HeLa cells were cultured in Ham's F-10 medium (Lonza, Basel, Switzerland) or Dulbecco's modified Eagle's medium with L-glutamine (BioWhittaker) supplemented with 10% fetal bovine serum (BioWhittaker), 25 mM HEPES buffer (BioWhittaker), 100 U/mL penicillin, 100 mg/mL streptomycin (Life Technologies) and 250 ng/mL fungizone (Life Technologies) in a humidified atmosphere of 5% CO 2 at 37°C.
Transfection of HeLa cells was performed in six-well plates using the jetPRIME DNA transfection kit (Polyplus transfection, Illkirch-Graffenstaden, France) according to the manufacturer's instructions. Transfection of skin fibroblasts was performed using the AMAXA NHDF Nucleofector Kit (Lonza, Basel, Switzerland) according to the manufacturer's instructions (program U23).
For functional complementation, we transfected patient's skin fibroblasts with the plasmid pcDNA3.1-hsACBD5, containing full-length human ACBD5 cDNA (1.5 kb). The medium was changed 24 hours after transfection. For immunofluorescence microscopy, cells were imaged 3 days after transfection. For the D3-C22:0 loading test, D3-C22:0 was added to the medium 1 day after transfection, and fatty acid analysis was performed 3 days later. C26:0 lysoPC was measured in cell pellets 4 days after transfection.
Genetic analysis
Genomic DNA was isolated from skin fibroblasts using the NucleoSpin Tissue genomic DNA purification kit (Macherey-Nagel, Germany, Düren). All forward and reverse primers used for sequencing (available upon request) were tagged with a -21M13 (5 0 -TGTAAAACGACGGCCAGT-3 0 ) sequence or M13rev (5 0 -CAGGAAACAGCTATGACC-3 0 ) sequence, respectively. PCR fragments were sequenced in two directions using '-21M13 0 and 'M13rev' primers by means of BigDye Terminator V.1.1 Cycle Sequencing Kits (Applied Biosystems, Foster City, California, USA) and analysed on an Applied Biosystems 3130×1 or 3730×1 DNA Analyzer, following the manufacturer's protocol (Applied Biosystems, Foster City, California, USA). ACBD5 sequence data were compared with the reference ACBD5 sequence (GenBank accession No. NM_145698.4) with nucleotide numbering starting at the first adenine of the translation initiation codon ATG.
Generation of ACBD5-deficient HeLa cells by CRISPR-Cas9
The CRISPR-Cas9 genome editing technology as described by Ran was used to introduce a disruption of the ACBD5 gene in HeLa cells. 21 To this end, two complementary oligonucleotides coding for a guide RNA upstream of a proto-spacer adjacent motif (PAM) site in exon 2 (5 0 -CGG, c.124_122) of the ACBD5 gene were designed using the online CRISPR design tool (http:// crispr.mit.edu/). The two oligos were annealed and subsequently cloned into the pX458 (-pSpCasq(BB)-2A-GFP) plasmid, 21 followed by Sanger sequencing of the insert to confirm the correct sequence. HeLa cells were transfected with 2 mg plasmid, and single green fluorescent protein (GFP)-positive cells were sorted into wells of a 96-well plate using fluorescence-activated cell sorting (FACS) flow cytometry (S800H Cell Sorter, Sony) as described. 21 After 3-4 weeks, DNA was isolated from the expanded single colonies, and exon 2 of the ACBD5 gene was PCR-amplified using Phire Hot Start II DNA Polymerase (ThermoFisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer's instructions and subsequently Sanger-sequenced. We sequenced multiple clonal cells and found several with compound heterozygous mutations in ACBD5, suggesting that the HeLa cells were not aneuploid for the ACBD5 gene. For subsequent studies, we used cells (HeLaΔACBD5) that were apparent homozygous for the c.128insA mutation ( p.V42fs*3), which was the most commonly found mutation among the clonal cells. Technically, however, we cannot exclude that these cells were hemizygous for the c.128insA mutation. The HeLaΔACBD5 cells were analysed by immunoblotting to confirm the absence of ACBD5 protein and used for further experiments. The two putative offtarget regions of the TLE6 and DBNDD2 genes predicted by the online CRISPR design tool were sequenced, but did not contain mutations.
Pexophagy assay
To assess pexophagy in cells, we set up a similar Red-Green lysosome assay as described in refs. 11 22 using mCherry-GFP-serine-lysine-leucine (SKL) as peroxisomal reporter. Cells were cultured in live cell chambers (CELLview cell culture dishes (Greiner Bio-One, Kremsmünster, AT), which allowed to follow the development in time and prevented any influence of fixation on intracellular pH. Cells were transfected with 2 mg mCherry-GFP-SKL plasmid as described above. Twenty-four hours after transfection, the cells were either cultured in the presence of lysosomal protease inhibitors in order to prevent mCherry-GFP degradation in the lysosome (2 mM E-64 and 250 mM leupeptin (Enzo Life Sciences, East Farmingdale, New York, USA) or in the presence of the autophagy inhibitor 3-methyladenine (3-MA, Sigma-Aldrich, St Louis, Missouri, USA).
Live cells were imaged with a Leica TCS SP8 filter-free spectral confocal microscope. Acquisition settings were adjusted to achieve a red and green signal of approximately equal intensity, and subsequently the same settings were used throughout the experiments. Red and green channel images were acquired simultaneously in order to prevent disturbances by peroxisomal movement. Excitation wavelengths of 489 or 587 nm were used for the green or red signal, respectively, and emission spectra were obtained at 499-550 nm or 597-671 nm, respectively (HyD SMD detectors, laser intensity 3%). The pixel size was between 42 and 44 nm. Ten to forty images of cells per condition were acquired in two or three different areas of the live cell chambers, each image containing one single fibroblast or one to four HeLa cells.
Image processing was performed off-line using a commercial software package (MATLAB R2015a, The MathWorks, Natick, Massachusetts, 2000, USA). In summary, background noise was removed, peroxisomes were labelled and the red to green intensity for each of the peroxisomes was measured and analysed. Background signals and non-peroxisomal signals were removed by processing the images of the red and green channel separately before merging them. To this end, we used multiple filters to remove the background signal, and additionally created a 'mask', which only selects peroxisomes. This mask consists exclusively of areas with high intensity of green and/or red signal. Areas with a minimum of 10 pixels were labelled as peroxisomes and used for quantification. The ratio of red to green signal (R/G) in each pixel was calculated, and the number of pixels with an average R/G >3 was quantified ('red-only' pixels). For this study, we defined fibroblasts with at least 20% 'red-only' pixels as pexophagy-induced cells. In all HeLa cells, the overall amount of 'red-only' signal was below 20%, but peroxisomes undergoing pexophagy were clearly discernible by their bright red colour. We defined HeLa cells as pexophagy-induced, when they displayed at least one of those bright red peroxisomes and quantified them manually (see also only online supplementary figure S3) .
RESULTS

Case description
The patient, a girl, is one of three siblings from healthy consanguineous parents from the United Arab Emirates. Her sisters are both neurologically healthy, but one sister has been found to have a homozygous mutation in MCR4 leading to morbid obesity. The patient was born full-term by spontaneous vaginal delivery after a pregnancy complicated only by gestational diabetes managed with dietary changes. She was born with a cleft palate, for which correction was performed at 6 months, but appeared otherwise normal in the first months of life. At age 7 months, she presented with abnormal eye movements and was diagnosed with retinal rod-cone dystrophy. She had delayed gains of motor skills; although she walked independently at 1 year, her gait was unsteady and she continued to need to hold on to objects to rise from the floor, which initially was attributed to her visual impairment. By 2 years of age, her gait had become progressively abnormal. She started to speak in sentences at the age of two and a half years, and her cognitive function appeared relatively preserved.
By 4 years of age, however, it became apparent that her vocabulary was limited and she was dysarthric, despite normal hearing. She had developed a progressive microcephaly with facial dysmorphisms, including a tubular nose, hypotelorism, prominent ears, bilateral ptosis and rotatory nystagmus. Her motor dysfunction was marked, with a positive Gowers and proximal weakness, as well as increased extrapyramidal and pyramidal tone in her arms and legs. Her gait was wide-based with truncal titubation and waddling, and finger-nose-finger testing was remarkable for mild dysmetria. Over time, her gait became increasingly unbalanced. She developed greater difficulty with walking, descending stairs and decreased endurance with increased falling, and by the age of 9 years could walk only with two-handed assistance or short distances with a walker. Brain MRI (see figure 1) at the age of 4 years revealed hypomyelination with diffuse T2 signal abnormality in deep white matter with relative sparing of the subcortical U fibres. Signal abnormality was also seen to involve the long tracts in the brainstem, including the pyramidal tracts, the medial lemniscus and the inferior cerebellar peduncles.
Peroxisomal investigations in blood and skin fibroblasts
Extensive laboratory testing including metabolic screening did not reveal clear abnormalities except for mildly increased plasma VLCFA levels (see table 1 ). VLCFA analysis was repeated in a later sample and remained abnormal. In addition, C26:0 lysoPC and C26-acylcarnitine levels in blood spot were increased. Other peroxisomal parameters in blood were normal (ie, plasma phytanic acid, pristanic acid and pipecolic acid, and plasmalogens in erythrocytes). Based on the abnormal VLCFA profile, a peroxisomal disorder was suspected, in particular, acyl-CoA oxidase 1 (ACOX1) deficiency, affecting the first enzyme in peroxisomal VLCFA oxidation, or carriership of X-linked adrenoleukodystrophy (X-ALD). Both defects were excluded by Sanger-sequencing of the genes involved (ie, ACOX1 and ABCD1). Subsequently, peroxisomal studies were performed in cultured primary skin fibroblasts of the patient. Immunofluorescence microscopy analyses with antibodies against the peroxisomal matrix protein catalase and the peroxisomal membrane proteins ABCD1 and ABCD3 revealed the normal presence of import-competent peroxisomes in fibroblasts of the patient. In addition, immunoblot analysis revealed normal peroxisomal processing of ACOX1 and peroxisomal thiolase, confirming normal peroxisome biogenesis in the fibroblasts of the patient. VLCFA analysis showed that also in fibroblasts the C26:0 level was clearly increased with an increased C26:0/C22:0 ratio (see table 1 ). In addition, C26:0 lysoPC was increased in fibroblasts showing that VLCFA levels in the phospholipid fraction are increased. To study the underlying cause of the C26:0 accumulation, peroxisomal fatty acid oxidation studies were performed with different radiolabelled substrates. Phytanic acid α-oxidation and pristanic acid β-oxidation activities were normal compared with the reference values, but C26:0 β-oxidation was reduced (table 1). The C26:0 β-oxidation activity was decreased to 33% of the mean activity in the control fibroblasts within the same experiment. However, the activities of the enzymes involved in peroxisomal β-oxidation of VLCFAs, that is, ACOX1, D-bifunctional protein (DBP) and sterol carrier protein X, were not decreased when measured in a fibroblast homogenate. To further study VLCFA metabolism, we performed a loading study with deuteriumlabelled C22:0 (D3-C22:0). Fibroblasts were incubated with 30 mM D3-C22:0 for 3 days followed by fatty acid analysis with tandem mass spectrometry. Both D3-C26:0 and D3-C28:0 levels were increased compared with the levels in the control fibroblasts analysed in the same experiment showing increased chain elongation from the substrate D3-C22:0, most likely because of increased substrate availability due to impaired peroxisomal breakdown of D3-C22:0 (table 2) . Also, unlabelled C26:0 levels were increased in this analysis with an increased C26:0/C22:0 ratio. The extent of the accumulation of the labelled and unlabelled VLCFAs was similar in fibroblasts of a patient with X-ALD analysed in the same experiment.
Genetic analysis and functional complementation studies
Because of the impaired peroxisomal β-oxidation of C26:0 and the absence of mutations in ACOX1 and ABCD1, we considered ACBD5, which encodes a peroxisomal membrane protein with a putative acyl-CoA binding domain, as a candidate gene. We performed molecular analysis of ACBD5 by Sanger-sequencing and identified a homozygous deleterious c.626-689_937-234delins 936+1075_c.936+1230inv mutation (NM145698.4, see online supplementary figure S1). This mutation causes the deletion of exons 7 and 8, and is predicted to create a premature stop codon ( p.D208Vfs*30). Both parents were heterozygous for this mutation, confirming homozygosity. Immunoblot analysis and immunofluorescence analysis with antibodies against ACBD5 demonstrated the absence of ACBD5 in fibroblasts of the patient (figure 2). To determine if the mutation in ACBD5 was the underlying cause of the accumulation of VLCFAs in the patient, we transfected wild-type ACBD5 cDNA into the patient's fibroblasts followed by C26:0 lysoPC measurement and a D3-C22:0 loading test. ACBD5 expression was confirmed by immunoblot analysis (not shown). Four days after transfection, the C26:0 lysoPC concentration had decreased from 29 in the mock-transfected cells to 18 mmol/g in the ACBD5-transfected cells (table 3) , which is just above the upper Figure 1 Brain MRI at the age of 4 years and 3 months (A). Please note the diffuse involvement of the deep white matter with abnormal T2 signal (B) and relatively more normal T1 signal (C) consistent with hypomyelination. The signal abnormalities demonstrate relative better myelination of the subcortical white matter (D, thin white arrow) and the anterior aspect of the corpus callosum (A and B). There is striking signal abnormality involving the posterior limb of the internal capsule, sparing the pyramidal tracts (dark dots in B). The splenium of the corpus callosum is also strikingly affected (A, thick white arrow, and B, thin white arrow). There are signal abnormalities of the long tracts of the brainstem, including the pyramidal tracts (E, thin white arrow) and the medial lemniscus (F, thin white arrow) in the pons and the superior (E, dotted white arrow) and inferior cerebellar (F, dotted white arrow) peduncles. There are no structural abnormalities of the brain, contrast enhancement or diffusion restriction abnormalities.
limit of the reference range in fibroblasts (2-14 mmol/g). Fatty acid analysis 3 days after loading the transfected cells with D3-C22:0 revealed a significant decrease in the levels of D3-C28:0 and D3-C26:0 compared with the mock-transfected cells (table 3) . Also, the level of unlabelled C26:0 was significantly reduced with a decrease in C26:0/C22:0 ratio. These results show that the impaired VLCFA metabolism in the patient's cells is caused by ACBD5 deficiency and can be rescued by introduction of wild-type ACBD5.
Functional analysis of ACBD5 in HeLa cells
To confirm that ACBD5 deficiency causes VLCFA accumulation and to study the specific role of ACBD5 in peroxisome metabolism further, we introduced ACBD5 deficiency in HeLa cells by CRISPR-Cas9 genome editing. For our analysis, we used HeLa cells which were apparent homozygous for a nucleotide insertion in exon 2 of ACBD5 (c.128InsA, p.V42fs*3), whichsimilar to the patient's cells-resulted in the complete absence of the ACBD5 protein in the HeLa cells (HeLaΔACBD5), as confirmed by immunoblotting (see online supplementary figure  S2 ). Peroxisomal investigations of these cells confirmed the findings in the primary patient's fibroblasts. The VLCFA profile was abnormal in HeLaΔACBD5 cells with an increased C26:0 level (0.18 mmol/g vs 0.053 in HeLa) and increased C26:0/C22:0 ratio (0.26 vs 0.07 in HeLa). C26:0 lysoPC was also increased in HeLaΔACBD5 cells (0.087 mmol/g vs 0.027 in HeLa). In addition, C26:0 β-oxidation activity was reduced in HeLaΔACBD5 cells (583 pmol/(hr.mg protein) vs 971 in HeLa), and loading with D3-C22:0 resulted in the accumulation of D3-C26:0 (0.34 mmol/g vs 0.15 in HeLa), just like in patient's fibroblasts. These results confirm that a deficiency of ACBD5 results in impaired peroxisomal VLCFA metabolism.
Role of ACBD5 in pexophagy?
Recently, it has been suggested that, based on sequence similarity with ATG37 from the yeast Pichia pastoris, ACBD5 might play a role in pexophagy. 11 We studied this aspect in both the ACBD5-deficient patient's fibroblasts and HeLaΔACBD5 cells. To this end, we used a previously described Red-Green lysosome pexophagy assay, in which a fusion protein composed of mCherry and GFP followed by a C-terminal peroxisomal targeting motif is expressed in cells. Expression of this fusion protein in cells predominantly results in yellow-labelled peroxisomes, whereas peroxisomes subject to pexophagy are 'red-only' due to quenching of the green GFP fluorescence in the acidic environment of lysosomes.
We did not observe a difference in the level of pexophagy between control and ACBD5-deficient patient's fibroblasts upon expression of the reporter construct, while control cells treated with the autophagy inhibitor 3-MA showed a markedly lower number of pexophagy-induced cells (see figure 3 and online supplementary figure S3) . We also performed the Red-Green lysosome assay in control and the ACBD5-deficient HeLa cells, a cell type used previously for this assay. 11 22 Also, in this cell system, the level of pexophagy in ACBD5-deficient HeLa cells was similar to the level in control HeLa cells, while it was clearly decreased when the cells were treated with the autophagy inhibitor 3-MA (see figure 3 and online supplementary figure S3 ).
DISCUSSION
We report the identification and characterisation of a patient with a deficiency of ACBD5 and show that ACBD5 deficiency is a novel single peroxisomal enzyme deficiency causing an impaired VLCFA metabolism. Screening of peroxisomal parameters in blood revealed an abnormal VLCFA profile and accumulation of C26:0 lysoPC. Furthermore, studies in the patient's fibroblasts revealed an impaired VLCFA metabolism as concluded from: (1) an abnormal VLCFA profile with increased concentration of C26:0 and increased C26:0/C22:0 ratio, (2) increased C26:0 lysoPC level showing an increased C26:0 concentration in the phospholipid fraction, (3) reduced peroxisomal C26:0 β-oxidation activity but normal pristanic acid oxidation activity and (4) accumulation of D3-C26:0 and D3-C28:0 after loading fibroblasts with D3-C22:0, indicative of increased chain elongation due to increased substrate availability.
The ACBD5 defect in the patient was demonstrated by molecular analysis of the encoding gene and analysis of protein expression. The patient was homozygous for a deleterious ACBD5 is a peroxisomal membrane protein with a cytosolic acyl-CoA binding domain. Based on our findings in fibroblasts of the patient and the ACBD5-deficient HeLa cells, we postulate that ACBD5 is involved in capturing C26-CoA in the cytosol through its acyl-CoA binding domain and presenting it to the VLCFA transporter ABCD1. ABCD1 then transports the C26-CoA into the peroxisome where it is β-oxidised by the sequential action of the peroxisomal β-oxidation enzymes ACOX1, DBP, sterol-carrier protein X and 3-ketoacyl-CoA thiolase. This postulated role of ACBD5 is supported by the fact that peroxisomal β-oxidation activity of C26:0 in the ACBD5 patient's cells was reduced to a similar degree as observed in cells of patients with X-ALD. In mitochondria, the acyl-CoA binding protein ACBP fulfils a similar function by binding palmitoyl-CoA and passing it on to carnitine palmitoyl-CoA transferase 1 for transport over the mitochondrial membrane to be β-oxidised.
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ACBD5 was recently suggested to play a role in pexophagy. 11 It was hypothesised that the absence of ACBD5 would abrogate pexophagy and lead over time to an accumulation of peroxisomes. However, our studies in the patient's fibroblasts lacking ACBD5 and in HeLaΔACBD5 cells did not confirm an involvement of ACBD5 in pexophagy, at least in these cell types.
In addition, we did not observe an obvious difference in peroxisome number between control and ACBD5-deficient cells. Instead, our findings clearly showed that ACBD5 deficiency caused an impaired VLCFA metabolism. VLCFA accumulation is not a biochemical abnormality exclusive to ACBD5 deficiency, but is also observed in other peroxisomal disorders, such as X-ALD, ACOX1 and DBP deficiency, and in Zellweger spectrum disorders (ZSDs). 3 In X-ALD, ACBD5 and ACOX1 deficiency, VLCFA accumulation is the only biochemical abnormality, whereas in DBP deficiency and ZSDs, multiple peroxisomal metabolic pathways are affected resulting in additional metabolic abnormalities. The patient presented with progressive leukodystrophy, ataxia, retinal dystrophy, cleft palate and facial dysmorphism, which are clinical symptoms that resemble those observed in patients with ACOX1 deficiency, but are different from X-ALD. 24 The underlying reason for this difference in clinical picture is unclear, but could be due to a different tissue/cell-type expression pattern of the proteins involved and a difference in the expression pattern of the proteins that can partly take over the function of the defective proteins (eg, ABCD2 and ABCD3 in case of ABCD1 deficiency and ACOX2 in case of ACOX1 deficiency). Also, the MRI abnormalities seen in this patient (figure 1) are distinct from those seen in X-ALD or ZSDs. 25 In a previous study aimed at determining the genetic causes of retinal dystrophy in a large cohort of patients by whole exome sequencing (WES), a homozygous splice site mutation was identified in ACBD5 in three siblings with retinal dystrophy and white matter changes. 15 Although no further clinical details were provided, this suggests that the clinical presentation of ACBD5 deficiency is consistent. Since the focus of previous report was on exome sequencing, neither metabolic investigations nor experiments to investigate the underlying pathological mechanism were presented. Our studies now show that ACBD5 deficiency belongs to the group of peroxisomal single enzyme deficiencies. This novel disorder should be included in addition to ACOX1 deficiency and X-ALD in the differential diagnostics in patients with clinical symptoms indicative of a peroxisomal disorder and an abnormal VLCFA profile. 
